George Clinical’s scientific leaders Dr. Mikhail Kosiborod and Dr. Carolyn Lam have been chosen to participate in the 18th annual World Congress Insulin Resistance Diabetes & Cardiovascular Disease (WCIRDC) virtual conference. This event runs December 3-6, 2020.
On Sunday December 6, Dr. Kosiborod will be presenting at Session #17, Cardiovascular Disease and Insulin Resistance on the topic, The Future of Cardiometabolic Care is Here: Announcing Cardiometabolic Center Alliance. Dr. Kosiborod will be chairing the panel discussion for Session #22, Heart Failure and Management and Dr. Lam will be presenting the topic, All We Need to Know about HFpEF.
The WCIRDC global meeting has brought researchers, physicians, clinicians, and other healthcare professionals together for nearly two decades. WCIRDC is dedicated to diabetes, obesity, lipids, cardiovascular-kidney and liver disease linking basic research to clinical practice in pursuit of this year’s theme: Exploring New Frontiers in Metabolism — Tomorrow’s Clinical Science Today.
Dr. Kosiborod’s research has a strong focus on the intersection of diabetes and cardiovascular disease. He is Vice President of Research at Saint Luke’s Health System; Director of Cardiometabolic Research and Co-Director of the Haverty Cardiometabolic Center of Excellence at Saint Luke’s Mid America Heart Institute; and Professor of Medicine at the University of Missouri-Kansas City. He is an internationally recognized expert in diabetes and cardiovascular disease, cardiometabolic and cardiorenal syndromes, as well as quality of care and outcomes. He received training in clinical research, epidemiology and health policy through the Robert Wood Johnson Clinical Scholars Program, as well as clinical training in cardiovascular medicine at Yale University School of Medicine.
As a practicing clinician and researcher, Dr. Kosiborod seeks to establish a practical system of implementing adoption of new treatments that have been proven to be life saving into practice in a more timely manner. He continues to be involved in the leadership of numerous clinical trials and multi-center registries, and serve as the Principal Investigator of investigator-initiated, multi-center trials in diabetes and cardiovascular disease, most recently of SGLT2 inhibition.
Meet with George Clinical! Contact us to schedule a time now.